Access Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the development and commercialization of proprietary products for the treatment and supportive care of cancer patients. Access has one approved product, two products in Phase development, and five preclinical development programs. The company s approved product is MuGard TM for the management of oral mucositis a common and debilitating side effect of many cancer therapies for which marketing authorization has been allowed by the FDA. Access ProLindac TM , a polymer linked platinum cancer drug is in Phase clinical testing in cancer patients, as is Phenylbutyrate, a pleotropic agent which current evidence suggests acts as both an HDAC inhibitor and a differentiating agent. The Company s preclinical development programs include Angiolix, a humanized monoclonal antibody which acts as an anti angiogenesis factor and is potentially targeted to a number of tumor types, including breast and ovarian Prodrax, a non toxic prodrug which is activated in the hypoxic zones of solid tumors to kill tumor cells Alchemix, a chemotherapeutic agent that combines two modes of action to overcome drug resistance, and oral insulin, which utilizes the company s Cobalamin TM oral drug delivery technology.
Quote | Abeona Therapeutics Inc. (NASDAQ:ABEO)
Last: | $4.64 |
---|---|
Change Percent: | 0.21% |
Open: | $4.65 |
Close: | $4.64 |
High: | $4.7 |
Low: | $4.32 |
Volume: | 408,695 |
Last Trade Date Time: | 12/04/2023 03:00:00 am |
News | Abeona Therapeutics Inc. (NASDAQ:ABEO)
2023-11-27 07:50:10 ET More on Abeona Therapeutics Abeona Therapeutics Inc. (ABEO) Q3 2023 Earnings Call Transcript Abeona Therapeutics GAAP EPS of -$0.48 beats by $0.05 Abeona submits FDA market application for rare skin disorder drug Seeking Alpha’s ...
- PDUFA target action date is May 25, 2024 - - FDA does not currently plan to hold Advisory Committee meeting for pz-cel BLA - CLEVELAND, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the U.S. Food and Drug Administration (FDA) has ac...
Message Board Posts | Abeona Therapeutics Inc. (NASDAQ:ABEO)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $ABEO News Article - Abeona Therapeutics Announces Update on AAV Ophthalmology Program | whytestocks | investorshangout | 03/14/2023 12:21:07 PM |
whytestocks: $ABEO News Article - PXMD, GETY: The Top 5 Short Squeeze Stocks to Watch This Week | whytestocks | investorshangout | 11/21/2022 6:35:49 PM |
You gots me CONFUSED, Young Lady!! YES, I | Invest-in-America | investorshub | 10/12/2022 2:34:13 PM |
you already posted there silly, so i replied | gail | investorshub | 10/12/2022 2:26:24 PM |
O.K., I'll take a look at THAT one | Invest-in-America | investorshub | 10/12/2022 2:24:19 PM |
News, Short Squeeze, Breakout and More Instantly...
Abeona Therapeutics Inc. Company Name:
ABEO Stock Symbol:
NASDAQ Market:
Abeona Therapeutics Inc. Website:
- PDUFA target action date is May 25, 2024 - - FDA does not currently plan to hold Advisory Committee meeting for pz-cel BLA - CLEVELAND, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the U.S. Food and Drug Administration (FDA) has ac...
Abeona’s first-ever U.S. Biologics License Application (BLA) submission completed in September 2023 FDA decision on priority review and acceptance of BLA for pz-cel (prademagene zamikeracel, formerly known as EB-101) in recessive dystrophic epidermolysis bullosa (RDEB) expected by ...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...